<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Numerous lines of evidence suggest that <z:chebi fb="0" ids="5686">heterocyclic compounds</z:chebi> used as <z:chebi fb="29" ids="35480">analgesic</z:chebi>, anti-inflammatory and anti-<z:hpo ids='HP_0002076'>migraine</z:hpo> agents can be potent regulators of the nitroxidative stress and targeting free nitrogen and oxygen radicals is a very promising strategy for future pain management </plain></SENT>
<SENT sid="1" pm="."><plain>Both classical <z:chebi fb="29" ids="35480">analgesics</z:chebi> (<z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi>, opioid drugs) and many <z:chebi fb="29" ids="35480">analgesic</z:chebi> adjuvants, including <z:chebi fb="0" ids="47781">desipramine</z:chebi>, <z:chebi fb="0" ids="36796">duloxetine</z:chebi>, <z:chebi fb="0" ids="5118">fluoxetine</z:chebi>, <z:chebi fb="0" ids="7936">paroxetine</z:chebi>, <z:chebi fb="0" ids="36791">escitalopram</z:chebi>, phenytoin or carbamazepine and α-<z:chebi fb="0" ids="30314">lipoic acid</z:chebi> can modulate the balance between pro-oxidant and <z:chebi fb="11" ids="22586">antioxidant</z:chebi> processes in the mammalian tissues and these properties of drugs such as <z:chebi fb="0" ids="49662">indomethacin</z:chebi>, meloxicam, tenoxicam, valdecoxib or some metabolites of <z:chebi fb="29" ids="35480">analgesic</z:chebi> drugs formed by the activity of tissue peroxidases may contribute to their clinical efficacy and drug-related toxic effects, including <z:mp ids='MP_0003300'>gastrointestinal ulcers</z:mp>, <z:hpo ids='HP_0001399'>hepatic failure</z:hpo>, <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, opiate-induced <z:mp ids='MP_0005407'>hyperalgesia</z:mp> and tolerance </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacities of novel <z:chebi fb="0" ids="5686">heterocyclic compounds</z:chebi>, including the compounds acting either by prevention of formation or catalyzed decomposition of <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi> <z:chebi fb="5" ids="22563">anion</z:chebi> (<z:chebi fb="0" ids="29330">ONOO</z:chebi>-), namely the <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi> decomposition catalysts or as <z:chebi fb="1" ids="18421">superoxide</z:chebi> (O2 •-)-scavengers which are the functional mimetics of <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) enzymes (SODm), as well as the derivatives of 6-<z:chebi fb="13" ids="29785">nitro</z:chebi>-3,4-methylenedioxyphenyl-Nacylhydrazone (LASSBio-881) or γ-butyrolactone (LPP1, BM113, BM113A, BM138 and BM138A) are also discussed as potent and promising future heterocyclic <z:chebi fb="29" ids="35480">analgesics</z:chebi> </plain></SENT>
</text></document>